Evidence map›Paper›PMID 39907283›Full record

ArticleJournal of virology2025

Longitudinal changes in the transcriptionally active and intact HIV reservoir after starting ART during acute infection.

Julie Janssens, Adam Wedrychowski, Sun Jin Kim, Cordelia Isbell, Rebecca Hoh, Satish K Pillai, Timothy J Henrich, Steven G Deeks, Nadia R Roan, Sulggi A Lee and 1 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Julie JanssensDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.ORCID 0000-0002-5211-8719
Adam WedrychowskiDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Sun Jin KimDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Cordelia IsbellDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Rebecca HohDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Satish K PillaiDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Timothy J HenrichDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Nadia R RoanDepartment of Urology, University of California, San Francisco (UCSF), San Francisco, California, USA.
Sulggi A LeeDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Steven A YuklDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.ORCID 0000-0002-4578-9872

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
The heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
Understanding and targeting the HIV-expressing reservoir to reduce immune activationR01AI183666 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT, Steven A Yukl · 2024 to 2026
$2.4M
Assessing the Interrelationship Between Adipose Tissue Thermogenesis and Fibrosis in the Metabolic Health of People Living with HIVR01DK141041 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT, SUNEIL Krishna KOLIWAD · 2024 to 2026
$2.3M
Investigating Mechanisms of HIV Persistence in the GutR01DK108349 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YUKL, STEVEN A · 2015 to 2019
$2.2M
Understanding HIV latency reversal and clearance of infected cells in vivoR01AI132128 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K, YUKL, STEVEN A · 2017 to 2021
$1.9M
A pharmacogenomics study of HIV latency: the role of PD-1 signalingK23GM112526 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, SULGGI ANGELA · 2014 to 2018
$908k
Mentoring Scientists for Careers in HIV Translational Clinical ResearchK24AI174971 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Timothy Jensen Henrich · 2023 to 2026
$766k
Gates Foundation INV-002703NIAID NIH HHS K24 AI174971NIAID NIH HHS P01 AI169606NIAID NIH HHS R01 AI132128NIAID NIH HHS R01 AI183666NIAID NIH HHS UM1 AI164560NIDDK NIH HHS R01 DK108349NIDDK NIH HHS R01 DK120387NIDDK NIH HHS R01 DK141041NIGMS NIH HHS K23 GM112526
6 · The paper itself

Abstract

Even in antiretroviral therapy (ART)-suppressed human immunodeficiency virus (HIV)-infected individuals, there are heterogeneous populations of HIV-expressing cells exhibiting variable degrees of progression through blocks to HIV transcriptional initiation, elongation, completion, and splicing. These HIV-transcribing cells likely contribute to HIV-associated immune activation and inflammation as well as the viral rebound that occurs after stopping ART. However, it is unclear whether the blocks to HIV transcription are present before ART and how the timing and duration of ART may affect the clearance of cells expressing HIV transcripts that differ in their processivity and/or presence of mutations. To investigate these questions, we quantified different types of HIV transcripts and the corresponding HIV DNA regions/proviruses in longitudinal blood samples obtained before ART initiation (T1) and after 6 months (T2) and 1 year (T3) of ART in 16 individuals who initiated ART during acute HIV infection. Before ART, the pattern of HIV transcripts suggested blocks to elongation and splicing, and only ~10% of intact proviruses were transcribing intact HIV RNA. During the first 6 months of ART, we detected progressively greater reductions in initiated, 5'-elongated, mid-transcribed, completed, and multiply spliced HIV transcripts. Completed HIV RNA decayed faster than initiated or 5'-elongated HIV RNA, and intact HIV RNA tended to decay faster than defective HIV RNA. HIV DNA and RNA levels at T1-T3 correlated inversely with baseline CD4+ T-cell counts. Our findings suggest the existence of immune responses that act selectively to reduce HIV transcriptional completion and/or preferentially kill cells making completed or intact HIV RNA.IMPORTANCEEven in virologically suppressed HIV-infected individuals, expression of viral products from both intact and defective proviruses may contribute to HIV-associated immune activation and inflammation, which are thought to underlie the organ damage that persists despite suppressive ART. We investigated how the timing of ART initiation and the duration of ART affect the heterogeneous populations of HIV-transcribing cells, including a detailed characterization of the different HIV transcripts produced before ART and the rate at which they decay after ART initiation during acute HIV infection. Even during untreated infection, most cells (~90%) have blocks at some stage of transcription. Furthermore, different HIV transcripts decline at different rates on ART, with the fastest decay of cells making completed and intact HIV RNA. Our results suggest that intrinsic or extrinsic immune responses act selectively to either reduce particular stages of HIV transcription or cause selective killing of cells making particular HIV transcripts.

Indexed as

Anti-HIV AgentsHIV InfectionsViral TranscriptionAdultCD4 Lymphocyte CountCD4-Positive T-LymphocytesHIVHumansLongitudinal StudiesMaleMiddle AgedProvirusesRNA, ViralYoung AdultAnti-HIV AgentsRNA, ViralHIV-associated immune activation/inflammationHIV persistence/latencyhuman immunodeficiency virus

Identifiers

PMID39907283
PMCPMC11915860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.